256 related articles for article (PubMed ID: 36098519)
41. A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus.
Fischer WA; Eron JJ; Holman W; Cohen MS; Fang L; Szewczyk LJ; Sheahan TP; Baric R; Mollan KR; Wolfe CR; Duke ER; Azizad MM; Borroto-Esoda K; Wohl DA; Coombs RW; James Loftis A; Alabanza P; Lipansky F; Painter WP
Sci Transl Med; 2022 Jan; 14(628):eabl7430. PubMed ID: 34941423
[TBL] [Abstract][Full Text] [Related]
42. Virologic Efficacy of Casirivimab and Imdevimab COVID-19 Antibody Combination in Outpatients With SARS-CoV-2 Infection: A Phase 2 Dose-Ranging Randomized Clinical Trial.
Portal-Celhay C; Forleo-Neto E; Eagan W; Musser BJ; Davis JD; Turner KC; Norton T; Hooper AT; Hamilton JD; Pan C; Mahmood A; Baum A; Kyratsous CA; Kim Y; Parrino J; Kampman W; Roque-Guerrero L; Stoici R; Fatakia A; Soo Y; Geba GP; Kowal B; DiCioccio AT; Stahl N; Lipsich L; Braunstein N; Herman GA; Yancopoulos GD; Weinreich DM;
JAMA Netw Open; 2022 Aug; 5(8):e2225411. PubMed ID: 35969402
[TBL] [Abstract][Full Text] [Related]
43. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
44. Olgotrelvir as a Single-Agent Treatment of Nonhospitalized Patients with Covid-19.
Jiang R; Han B; Xu W; Zhang X; Peng C; Dang Q; Sun W; Lin L; Lin Y; Fan L; Lv D; Shao L; Chen Y; Qiu Y; Han L; Kong W; Li G; Wang K; Peng J; Lin B; Tong Z; Lu X; Wang L; Gao F; Feng J; Li Y; Ma X; Wang J; Wang S; Shen W; Wang C; Yan K; Lin Z; Jin C; Mao L; Liu J; Kushnareva Y; Kotoi O; Zhu Z; Royal M; Brunswick M; Ji H; Xu X; Lu H
NEJM Evid; 2024 Jun; 3(6):EVIDoa2400026. PubMed ID: 38804790
[TBL] [Abstract][Full Text] [Related]
45. Ensitrelvir eradicates persistent SARS-CoV-2 infection in a follicular lymphoma patient treated with anti-CD20 antibodies.
Sakamaki I; Negoro E; Iwasaki H; Yamauchi T
J Infect Chemother; 2024 Feb; 30(2):147-149. PubMed ID: 37690521
[TBL] [Abstract][Full Text] [Related]
46. Sporadic Occurrence of Ensitrelvir-Resistant SARS-CoV-2, Japan.
Doi A; Ota M; Saito M; Matsuyama S
Emerg Infect Dis; 2024 Jun; 30(6):1289-1291. PubMed ID: 38669127
[TBL] [Abstract][Full Text] [Related]
47. SARS-CoV-2-neutralising antibody BGB-DXP593 in mild-to-moderate COVID-19: a multicentre, randomised, double-blind, phase 2 trial.
Vega R; Antila M; Perez C; Mookadam M; Xie F; Zhang W; Rizwan A; Yao Z; Rasko JEJ
EClinicalMedicine; 2023 Mar; 57():101832. PubMed ID: 36820098
[TBL] [Abstract][Full Text] [Related]
48. Quantum Chemical Interaction Analysis between SARS-CoV-2 Main Protease and Ensitrelvir Compared with Its Initial Screening Hit.
Watanabe C; Tanaka S; Okiyama Y; Yuki H; Ohyama T; Kamisaka K; Takaya D; Fukuzawa K; Honma T
J Phys Chem Lett; 2023 Apr; 14(15):3609-3620. PubMed ID: 37023394
[TBL] [Abstract][Full Text] [Related]
49. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
Trials; 2021 May; 22(1):343. PubMed ID: 34001215
[TBL] [Abstract][Full Text] [Related]
50. Oral Probenecid for Nonhospitalized Adults with Symptomatic Mild-to-Moderate COVID-19.
Martin DE; Pandey N; Chavda P; Singh G; Sutariya R; Sancilio F; Tripp RA
Viruses; 2023 Jul; 15(7):. PubMed ID: 37515194
[TBL] [Abstract][Full Text] [Related]
51. SARS-CoV-2 viral dynamics in a placebo-controlled phase 2 study of patients infected with the SARS-CoV-2 Omicron variant and treated with pomotrelvir.
Borroto-Esoda K; Wilfret D; Tong X; Plummer A; Kearney B; Kwong AD
Microbiol Spectr; 2024 Feb; 12(2):e0298023. PubMed ID: 38197702
[TBL] [Abstract][Full Text] [Related]
52. In vitro and in vivo characterization of SARS-CoV-2 resistance to ensitrelvir.
Kiso M; Yamayoshi S; Iida S; Furusawa Y; Hirata Y; Uraki R; Imai M; Suzuki T; Kawaoka Y
Nat Commun; 2023 Jul; 14(1):4231. PubMed ID: 37454219
[TBL] [Abstract][Full Text] [Related]
53. Phase 2 Safety and Antiviral Activity of SAB-185, a Novel Polyclonal Antibody Therapy for Nonhospitalized Adults With COVID-19.
Taiwo BO; Chew KW; Moser C; Wohl DA; Daar ES; Li JZ; Greninger AL; Bausch C; Luke T; Hoover K; Neytman G; Giganti MJ; Olefsky M; Javan AC; Fletcher CV; Eron JJ; Currier JS; Hughes MD; Smith DM;
J Infect Dis; 2023 Jul; 228(2):133-142. PubMed ID: 36661240
[TBL] [Abstract][Full Text] [Related]
54. Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers: A Randomized Clinical Trial.
Abella BS; Jolkovsky EL; Biney BT; Uspal JE; Hyman MC; Frank I; Hensley SE; Gill S; Vogl DT; Maillard I; Babushok DV; Huang AC; Nasta SD; Walsh JC; Wiletyo EP; Gimotty PA; Milone MC; Amaravadi RK;
JAMA Intern Med; 2021 Feb; 181(2):195-202. PubMed ID: 33001138
[TBL] [Abstract][Full Text] [Related]
55. Molecular mechanism of ensitrelvir inhibiting SARS-CoV-2 main protease and its variants.
Lin M; Zeng X; Duan Y; Yang Z; Ma Y; Yang H; Yang X; Liu X
Commun Biol; 2023 Jul; 6(1):694. PubMed ID: 37407698
[TBL] [Abstract][Full Text] [Related]
56. Efficacy and safety of nitazoxanide plus atazanavir/ritonavir for the treatment of moderate to severe COVID-19 (NACOVID): A structured summary of a study protocol for a randomised controlled trial.
Olagunju A; Fowotade A; Olagunoye A; Ojo TO; Adefuye BO; Fagbamigbe AF; Adebiyi AO; Olagunju OI; Ladipo OT; Akinloye A; Adeagbo BA; Onayade A; Bolaji OO; Happi C; Rannard S; Owen A
Trials; 2021 Jan; 22(1):3. PubMed ID: 33397457
[TBL] [Abstract][Full Text] [Related]
57. In silico Study to Evaluate the Antiviral Activity of Novel Structures against 3C-like Protease of Novel Coronavirus (COVID-19) and SARS-CoV.
Chunduru K; Sankhe R; Begum F; Sodum N; Kumar N; Kishore A; Shenoy RR; Rao CM; Saravu K
Med Chem; 2021; 17(4):380-395. PubMed ID: 32720605
[TBL] [Abstract][Full Text] [Related]
58. A multi-center, randomized controlled trial by the Integrative Management in Japan for Epidemic Disease (IMJEDI study-RCT) on the use of Kampo medicine, kakkonto with shosaikotokakikyosekko, in mild-to-moderate COVID-19 patients for symptomatic relief and prevention of severe stage: a structured summary of a study protocol for a randomized controlled trial.
Takayama S; Namiki T; Ito T; Arita R; Nakae H; Kobayashi S; Yoshino T; Ishigami T; Tanaka K; Kainuma M; Nochioka K; Takagi A; Mimura M; Yamaguchi T; Ishii T
Trials; 2020 Oct; 21(1):827. PubMed ID: 33008479
[TBL] [Abstract][Full Text] [Related]
59. Lessons learnt from the preclinical discovery and development of ensitrelvir as a COVID-19 therapeutic option.
Ferraro S; Convertino I; Cappello E; Valdiserra G; Bonaso M; Tuccori M
Expert Opin Drug Discov; 2024; 19(1):9-20. PubMed ID: 37830361
[TBL] [Abstract][Full Text] [Related]
60. SPIKE-1: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusion.
Halford S; Wan S; Dragoni I; Silvester J; Nazarov B; Anthony D; Anthony S; Ladds E; Norrie J; Dhaliwal K;
Trials; 2021 Aug; 22(1):550. PubMed ID: 34412682
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
